Inspiratory Muscle Training After Vertebroplasty in Osteoporotic Fracture Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorIstinye University

About this trial

This study investigates the long-term effects of inspiratory muscle training (IMT) on pulmonary function, functional capacity, and quality of life in individuals with osteoporotic vertebral compression fractures who have undergone percutaneous vertebroplasty.

Participants aged 50 and older, diagnosed with osteoporosis and having undergone thoracic vertebroplasty within the past 3 months, will be randomly assigned to either an intervention group (IMT + standard rehabilitation) or a control group (standard rehabilitation only).

The primary outcome measure is spirometry-based pulmonary function. Secondary outcome measures include inspiratory muscle strength, functional walking capacity (6-minute walk test), diaphragmatic structure and elasticity, and quality of life (SGRQ, NHP).

This randomized controlled trial will be conducted at the Cardiopulmonary Rehabilitation Unit of Nuh Naci Yazgan University and aims to provide scientific evidence for integrating IMT into routine post-vertebroplasty rehabilitation protocols.

Eligibility criteria

Qualifiers

Being 50 years of age or older at the time of the study,

Having a diagnosis of osteoporosis confirmed by a specialist physician,

Having undergone percutaneous vertebroplasty surgery due to an osteoporotic vertebral compression fracture in the thoracic region within the past 3 months,

Being cooperative with the questionnaires and assessment methods to be used in the study,

Disqualifiers

Having a history of diagnosed unstable cardiac disease,

Having a diagnosed pulmonary or neurological disorder,

Having experienced an acute infection within the past 15 days,

Being unable to participate in exercise interventions due to mental or cognitive impairment.

Trial design

Treatments tested in this trial

  • Inspiratory Muscle Training (IMT)
  • control group

Treatment groups

24 Participants
are divided into 2 treatment groups

Sponsors and collaborators